Neurocrine Biosciences
NBIX

Neurocrine Biosciences (NBIX) stock price, chart and financials

Price chart

−0.74% over 1Y
Oct 15, 2025Low $123.10 · High $185.50Oct 15, 2026

Financials

Company profile

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Frequently asked questions

  • Is Neurocrine Biosciences (NBIX) profitable?

    Yes. Neurocrine Biosciences earned $705.5M in net income over the trailing twelve months, a net margin of 20.91%.

  • How much revenue does Neurocrine Biosciences (NBIX) make?

    Neurocrine Biosciences generated $3.4B in revenue over the trailing twelve months, up 39.49% year over year.

  • What is NBIX's P/E ratio?

    Neurocrine Biosciences trades at 19.7 times trailing twelve-month earnings, on an EPS of $7.05.

  • How do I buy stock in Neurocrine Biosciences (NBIX)?

    NBIX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.